Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
3.145
+0.085 (2.78%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Arbutus Biopharma Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Arbutus Biopharma stock have an average target of 5.50, with a low estimate of 5.00 and a high estimate of 7.00. The average target predicts an increase of 74.88% from the current stock price of 3.15.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Arbutus Biopharma stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $5 | Strong Buy | Maintains | $5 | +58.98% | Mar 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +58.98% | Jan 21, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $4.5 → $5 | Strong Buy | Maintains | $4.5 → $5 | +58.98% | Nov 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +58.98% | Nov 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +58.98% | Nov 7, 2024 |
Financial Forecast
Revenue This Year
7.07M
from 6.17M
Increased by 14.57%
Revenue Next Year
8.19M
from 7.07M
Increased by 15.84%
EPS This Year
-0.33
from -0.38
EPS Next Year
-0.42
from -0.33
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 8.8M | 8.4M | 9.3M | ||
| Avg | 7.1M | 8.2M | 9.0M | ||
| Low | 6.2M | 7.9M | 8.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 42.9% | 19.2% | 13.2% | ||
| Avg | 14.6% | 15.8% | 10.0% | ||
| Low | 0.0% | 11.3% | 5.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.31 | -0.43 | -0.19 | ||
| Avg | -0.33 | -0.42 | -0.18 | ||
| Low | -0.41 | -0.40 | -0.18 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.